Ahmed Hend, Shafiey Ahmed S, Abdelrahim Mohamed E A
Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Discov Oncol. 2025 Feb 13;16(1):175. doi: 10.1007/s12672-025-01876-x.
Autologous hematopoietic stem cell transplantation (AHSCT) is a valuable treatment option for several hematological malignancies, particularly in relapsed or refractory cases. Autologous hematopoietic stem cell transplantation (AHSCT) is effective in improving survival rates in selected patients, particularly those with aggressive lymphomas and multiple myeloma. Studies suggest AHSCT may outperform alternative therapies, but ongoing research is essential to refine patient selection. Many patients enjoy prolonged remission and improved quality of life, indicating the need for long-term follow-up to assess late effects and overall survival. This work aimed to establish meta-analysis to methodically evaluate the safety and effectiveness of autologous stem cell therapy (AHSCT) in the management of malignant lymphoma following high-dose chemotherapy and to produce reliable findings that may serve as a foundation for clinical application and reference.
A systematic literature search was performed from February 2017 to August 2024, and malignant lymphoma was identified as the study subjects' diagnosis. The experimental group was identified as AHSCT afterwards high-dose chemotherapy, while the control group underwent standard chemotherapy (with no restrictions on the chemotherapy regimen). The outcome indicators were progression-free survival (PFS), complete remission rate (complete response (CR) + partial response (PR)), and overall survival (OS).
Fifteen literature pieces in all, consisting of 1229 subjects in the control group and 896 subjects in the experimental group, were included. Conventional chemotherapy (chemotherapy regimen not limited) was the intervention strategy used in the control group. The odds ratio (OR) was 2.23, with a 95% confidence interval (CI) of [1.54, 3.22], Z = 4.25; P < 0.0001, indicating that the groups differed in overall survival and progression-free survival rates. Similarly, the progression-free survival rate was 2.70, with a 95% CI of 1.86-3.92, Z = 4.25; P < 0.0001, and overall survival was 2.23.
Patients with malignant lymphoma who receive chemotherapy can substantially extend their overall survival and progression-free survival rates with AHSCT treatment.
自体造血干细胞移植（AHSCT）是治疗多种血液系统恶性肿瘤的一种有价值的选择，尤其是在复发或难治性病例中。自体造血干细胞移植（AHSCT）对于提高特定患者的生存率有效，特别是侵袭性淋巴瘤和多发性骨髓瘤患者。研究表明，AHSCT可能优于其他替代疗法，但持续的研究对于优化患者选择至关重要。许多患者实现了长期缓解并改善了生活质量，这表明需要进行长期随访以评估晚期效应和总生存期。本研究旨在进行荟萃分析，以系统地评估自体干细胞疗法（AHSCT）在大剂量化疗后治疗恶性淋巴瘤中的安全性和有效性，并得出可靠的结果，为临床应用和参考提供依据。
于2017年2月至2024年8月进行系统的文献检索，将恶性淋巴瘤确定为研究对象的诊断。实验组为大剂量化疗后进行AHSCT，而对照组接受标准化疗（化疗方案无限制）。结局指标为无进展生存期（PFS）、完全缓解率（完全缓解（CR）+部分缓解（PR））和总生存期（OS）。
共纳入15篇文献，对照组1229例受试者，实验组896例受试者。对照组采用的干预策略为传统化疗（化疗方案不限）。比值比（OR）为2.23，95%置信区间（CI）为[1.54, 3.22]，Z = 4.25；P < 0.0001，表明两组在总生存期和无进展生存率方面存在差异。同样，无进展生存率为2.70，95%CI为1.86 - 3.92，Z = 4.25；P < 0.0001，总生存期为2.23。
接受化疗的恶性淋巴瘤患者通过AHSCT治疗可显著延长其总生存期和无进展生存率。
